Idenix Pharmaceuticals' CEO Provides Update On IDX184 Clinical Development Program Conference (Transcript)

Idenix Pharmaceuticals, Inc. (IDIX)

Update on IDX184 Clinical Development Program Conference Call

August 16, 2012 08:30 am ET


Daniella Beckman - SVP & CFO

Ron Renaud - President & CEO

Doug Mayers - EVP & CMO

David Standring - EVP & CSO


Geoff Meacham - JPMorgan

Katherine Xu - William Blair

Yaron Werber - Citi

Howard Liang - Leerink Swann

Matt Roden - UBS

Daniel Brims - Brean Murray

Liisa Bayko - JMP

David Friedman - Morgan Stanley

Ying Huang - Barclays

Jim Birchenough - BMO Capital

Mark Schoenebaum - ISI Group

Yaron Werber - Citi



Good day ladies and gentlemen and welcome to the Idenix provides update on IDX184 clinical development conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, today’s call is being recorded.

I would now like to turn the conference over to Ms. Daniella Beckman. Ma'am, you may begin.

Daniella Beckman

Thank you. Good morning and welcome to Idenix Pharmaceuticals conference call to discuss the clinical development and status of our lead drug candidate, IDX184. My name is Daniella Beckman and I am the Chief Financial Officer at Idenix.

On this morning’s call is Ron Renaud, President and Chief Executive Officer; Doug Mayers, Chief Medical Officer, who has dialed in remotely and David Standring, Chief Scientific Officer.

Before we begin, I'll review our Safe Harbor statement. Today’s discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of factors that could cause actual results to differ materially.

If you liked this article you might like

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

Health Care Stocks: A Year in Review and Predictions for 2015

'Fast Money' Recap: Next Stop, S&P 2,100?

Cramer: Every Which Way But Short

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout